Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirasemtiv Phase 2 in ALS
NCT01378676Phase 2Completed
- Sponsor
- Cytokinetics
- Start
- Jun 2011
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tirasemtiv in amyotrophic lateral sclerosis (ALS) (4 arms), sponsored by Cytokinetics. Primary endpoint: Number of Participants with Adverse Events at 21 days. Started Jun 2011; status: completed.
02
Drugs
tirasemtiv
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT01378676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01378676.